[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575328":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":53,"collaborators":19,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":19,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":19,"enrollmentInfo":64,"targetDuration":19,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":19,"overallStatus":73,"whyStopped":19,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Total consolidative MPDT","EXPERIMENTAL","Participants will discontinue systemic anti-cancer therapy for metastatic RCC, and standard of care definitive procedures or metastatic RCC. These procedures include one or more of the following: surgery (e.g. nephrectomy, metastasectomy, lymph node dissection), percutaneous cryoablation and\u002For radiotherapy (SAbR or other definitive radiotherapy).",[13],"Procedure: Total consolidative MPDT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","After stopping systemic anti-cancer therapy for metastatic RCC, participant will receive one or more of the following: surgery (e.g. nephrectomy, metastasectomy, lymph node dissection), percutaneous cryoablation and\u002For radiotherapy (SAbR or other definitive radiotherapy).",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Naomi Haas, MD","Penn Medicine","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Matthew Doyle","CONTACT","610-357-6354","Matthew.Doyle@Pennmedicine.upenn.edu",{"name":22,"role":28,"phone":32,"phoneExt":19,"email":33},"2156627615","Naomi.Haas@pennmedicine.upenn.edu",[35],{"facility":36,"status":19,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Abramson Cancer Center at University of Pennsylvania","Philadelphia","Pennsylvania","19104","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-75.16362,39.95238,{"lat":46,"lon":45},[49,50],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":19,"email":33},"Naomi Haas","215-662-7615",{"type":54,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100575328","consolidative-metastasis-and-primary-directed-therapy-mpdt-for-renal-cell-carcinoma-rcc-100575328",false,"NCT06770855","Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)","A Phase II Study of Total Consolidative Metastasis-and-primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC).","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma (mixed histology acceptable but must have clear cell component)\n* Metastatic clear cell RCC with 5 or fewer metastases at enrollment (excluding pulmonary nodules \\\u003C1.0cm)\n* Stable disease or partial response as assessed by investigators following at least 6 months of immune checkpoint blockade-based therapy.\n* Has disease amenable for total consolidative focal therapy (this will be determined by a multidisciplinary team which may include a combination of medical oncologists, urologists, interventional radiologists, and radiation oncologists).\n* ECOG performance status \\\u003C 2\n* Must have archival tissue (slide or Formalin-Fixed Paraffin-Embedded tissue) preceding prior systemic treatment for comparison to tissue from consolidation\n* Consolidation surgery and biopsies are strongly encouraged to be within 42 days +\u002F- 7 days of holding systemic therapy.\n\nExclusion Criteria:\n\n* Subjects who have progressed during the first 6 months of immune checkpoint-blockade based therapy as determined by study investigator.\n* Subjects who have a need for urgent focally directed therapy (i.e. symptomatic brain or spinal metastases). Stable spinal metastases resected and\u002For treated with SBRT in advance of or concurrently with immune checkpoint-blockade based therapy are allowed to participate.\n* Any female of child-bearing potential who has a positive urine pregnancy test within 72 hours before screening. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Participants must be excluded\u002Fdiscontinued from the trial in the event of a positive or borderline positive serum pregnancy test result.","ALL","18 Years",{"count":65,"type":66},23,"ESTIMATED","INTERVENTIONAL",[69],"NA","This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response\u002Fstable disease after at least 6 months of immune checkpoint blockade-based therapy for metastatic clear cell RCC. The investigators hypothesize that patients who undergo total consolidative MPDT followed by systemic therapy discontinuation will have a 12-month treatment-free survival rate of 32% compared to a null hypothesis of 13%",[72],"Renal Cell Carcinoma","NOT_YET_RECRUITING","2026-06-18",{"date":76,"type":77},"2026-06-23","ACTUAL",{"date":79,"type":66},"2026-06-30",{"date":81,"type":66},"2028-09",{"name":5,"class":6},1]